Comparison Between Natural and Artificial Surfactant Preparations in Premature Rabbit Fetuses

  • B. Disse
  • E. Weller
  • L. Lützen
  • H. Ziegler
  • H. Eberhardt

Abstract

The effectiveness of several surfactant preparations for the treatment of hyaline membrane disease in premature newborns has been shown in clinical studies [1–7]. Some of these studies allow for more than one application or show a decline in the beneficial effect of replacement therapy after several hours, suggesting that at least some of the very premature babies require more than one dose of surfactant. The potential risk of substitution with exogenous surfactant may depend on the number of applications and the dose applied. Thus an optimal surfactant for replacement therapy should have high activity at a low phospholipid concentration. Artificial (chemical synthesis, cell culture synthesis) and natural (from biological sources) surfactant preparations have been extensively optimized and qualified by physical methods, such as surface tension/surface area-measurements (e. g. [8–10]). However, a convincing correlation between biochemical or physical parameters and biological surfactant activity could not be established [11, 12].

Keywords

Cholesterol Surfactant Toxicity Catheter Respiration 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Enhorning G, Shennan A, Possmayer F, Dunn M, Chen CP, Milligan J (1985) Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: randomized clinical trial. Pediatrics 76: 145–153PubMedGoogle Scholar
  2. 2.
    Kwong MS, Egan EA, Notter RH, Shapiro DL (1985) Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants. Pediatrics 76: 585–592PubMedGoogle Scholar
  3. 3.
    Shapiro DL, Notter RH, Morin III FC, Deluga KS, Golub LM, Sinkin RA, Weiss KI, Cox C (1985) Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics 76: 593–599PubMedGoogle Scholar
  4. 4.
    Merrit TA, Hallmann M, Bloom BT et al. (1986) Prophylactic treatment of very premature infants with human surfactant. N Engl J Med 315: 785–790CrossRefGoogle Scholar
  5. 5.
    Raju TNK, Vidyasagar D, Bhat R, Sobel D, McCulloch KM, Anderson M, Maeta H, Levy PS (1987) Double-blind controlled trial of single-dose treatment with bovine surfactant in severe hyaline membrane disease. Lancet 1: 651–656PubMedCrossRefGoogle Scholar
  6. 6.
    Gitlin JD, Soll RF, Parad RB, Horbar JD, Feldman HA, Lucey JF, Taeusch HW (1987) Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease. Pediatrics 79: 31–37PubMedGoogle Scholar
  7. 7.
    Ten centre study group (1987) Ten centre trial of artificial surfactant (artificial lung expanding compound) in very premature babies. Br Med J [Clin Res] 294: 991–996CrossRefGoogle Scholar
  8. 8.
    Reifenrath R, Zimmermann I (1976) Dynamic surface tension properties of mixed lecithin-cholesterol films related to the respiratory mechanics. Respiration 33: 303–314PubMedCrossRefGoogle Scholar
  9. 9.
    Bangham AD, Morley CJ, Phillips MC (1979) The physical properties of an effective lung surfactant. Biochim Biophys Acta 573: 552–556PubMedGoogle Scholar
  10. 10.
    Keough KMW (1984) Physical chemical properties of some mixtures of lipids and their potential for use as exogenous pulmonary surfactants. Prog Respir Res 18: 257–262Google Scholar
  11. 11.
    Nohara K, Berggren P, Curstedt T, Grossmann G, Nilsson R, Robertson B (1986) Correlations between physical and physiological properties of various preparations of lung surfactant. Eur J Respir Dis 69: 321–335PubMedGoogle Scholar
  12. 12.
    Lachmann B (1986) New aspects of pathophysiology and therapy of respiratory distress syndrome. In: Cosmi EV, Di Renzo GC (eds) Selected topics in perinatal medicine. CIC, Rome, pp 177–198Google Scholar
  13. 13.
    Nilsson R (1982) The artificially ventilated preterm rabbit neonate as experimental model of hyaline membrane disease. Acta Anaesthesiol Scand 26: 89–103PubMedCrossRefGoogle Scholar
  14. 14.
    Nilsson R, Berggren P, Curstedt T, Grossmann G, Renheim G, Robertson B (1985) Surfactant treatment and ventilation by high frequency oscillation in premature newborn rabbits; effect on survival, lung aeration and bronchiolar epithelial lesions. Pediatr. Res 19: 143–147Google Scholar
  15. 15.
    Revak SD, Merrit AT, Hallman M, Cochrane CG (1986) Reconstitution of surfactant activity using purified human apoprotein and phospholipids measured in vitro and in vivo. Am Rev Respir Dis 134: 1258–1265PubMedGoogle Scholar
  16. 17.
    Durand DJ, Clyman RI, Heymann MA, Clements JA, Mauray F, Kittermann J, Ballard P (1985) Effects of a protein-free, synthetic surfactant on survival and pulmonary function in preterm lambs. J Pediatr 107: 775–780PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • B. Disse
  • E. Weller
  • L. Lützen
  • H. Ziegler
  • H. Eberhardt

There are no affiliations available

Personalised recommendations